Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative

Vague Definitions, Increasing Uncertainty

Executive Summary

The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.

You may also be interested in...



Didi, Data And New China Cross-Border Transfer Regulations

Beijing imposes $1.2bn in fines on China's largest ride-hailing operator Didi for personal data security violations, putting the spotlight once again on the need to pay close attention to the latest draft regulations in the area, which could have a profound impact on any foreign businesses - including pharma - operating in the world’s second-largest economy.

Chinese Health Tech Giant Delays US IPO Amid DiDi Fallout

Big data player and “Flatiron of China” is putting off its plans to go public amid regulatory scrutiny over DiDi and other companies listed in the US, but biotech firms need to worry less, says one investor.

China Detains Legend Biotech CEO, Exposes Genetic Material Minefield

Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel